Agios Pharmaceuticals (AGIO) announced its anticipated key 2025 milestones and value-driving catalysts through 2026. FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND in Adult ...
Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares closed yesterday at $35.90. Discover outperforming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback